CL2021002667A1 - Formas cristalinas de 5-bromo-2,6-di(1h -pirazol-1-il)pirimidin-4amina y nuevas sales (divisional solicitud n° 201903468). - Google Patents

Formas cristalinas de 5-bromo-2,6-di(1h -pirazol-1-il)pirimidin-4amina y nuevas sales (divisional solicitud n° 201903468).

Info

Publication number
CL2021002667A1
CL2021002667A1 CL2021002667A CL2021002667A CL2021002667A1 CL 2021002667 A1 CL2021002667 A1 CL 2021002667A1 CL 2021002667 A CL2021002667 A CL 2021002667A CL 2021002667 A CL2021002667 A CL 2021002667A CL 2021002667 A1 CL2021002667 A1 CL 2021002667A1
Authority
CL
Chile
Prior art keywords
crystalline forms
pyrazol
pyrimidin
bromo
4amine
Prior art date
Application number
CL2021002667A
Other languages
English (en)
Inventor
Kai Cui
Weiyong Kong
Laria Julio Cesar Castro-Palomino
Original Assignee
Novartis Ag
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Palobiofarma Sl filed Critical Novartis Ag
Publication of CL2021002667A1 publication Critical patent/CL2021002667A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta solicitud se refiere a diversas formas cristalinas de 5–bromo–2,6–di(1H–pirazol–1–il)pirimidin–4–amina y su sal, así como a composiciones y métodos de uso de las mismas. En algunas formas de realización, las formas cristalinas también contienen agua (“hidratos”). Estos materiales son útiles en el tratamiento de diversas enfermedades, que incluyen carcinomas, específicamente cáncer de pulmón y más específicamente cáncer de pulmón de células no pequeñas.
CL2021002667A 2017-05-31 2021-10-12 Formas cristalinas de 5-bromo-2,6-di(1h -pirazol-1-il)pirimidin-4amina y nuevas sales (divisional solicitud n° 201903468). CL2021002667A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2017086624 2017-05-31

Publications (1)

Publication Number Publication Date
CL2021002667A1 true CL2021002667A1 (es) 2022-07-01

Family

ID=62778954

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019003468A CL2019003468A1 (es) 2017-05-31 2019-11-27 Formas cristalinas de 5-bromo-2,6-di(1h -pirazol-1-il)pirimidin-4-amina y nuevas sales.
CL2021002667A CL2021002667A1 (es) 2017-05-31 2021-10-12 Formas cristalinas de 5-bromo-2,6-di(1h -pirazol-1-il)pirimidin-4amina y nuevas sales (divisional solicitud n° 201903468).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019003468A CL2019003468A1 (es) 2017-05-31 2019-11-27 Formas cristalinas de 5-bromo-2,6-di(1h -pirazol-1-il)pirimidin-4-amina y nuevas sales.

Country Status (17)

Country Link
US (2) US10933064B2 (es)
EP (1) EP3630751B1 (es)
JP (1) JP7273732B2 (es)
KR (1) KR20200018503A (es)
CN (1) CN110944995B (es)
AR (1) AR111906A1 (es)
AU (1) AU2018277241B2 (es)
BR (1) BR112019025149A2 (es)
CA (1) CA3065475A1 (es)
CL (2) CL2019003468A1 (es)
IL (2) IL270795B2 (es)
JO (1) JOP20190279A1 (es)
MX (1) MX2021014104A (es)
RU (2) RU2019138329A (es)
TW (1) TWI814725B (es)
WO (1) WO2018220546A1 (es)
ZA (1) ZA201907610B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180371093A1 (en) * 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
JOP20190279A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
ATE293962T1 (de) * 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
BRPI0417478A (pt) 2003-12-15 2007-05-08 Almirall Prodesfarma Ag 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ES2546333T3 (es) 2005-07-01 2015-09-22 E. R. Squibb & Sons, L.L.C. Anticuerpos monoclonales humanos para ligandos 1 (PD-L1) de muerte programada
EP1989210A2 (en) * 2006-03-02 2008-11-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
US20080221103A1 (en) 2007-03-09 2008-09-11 Orchid Research Laboratories Ltd. New heterocyclic compounds
WO2008116186A1 (en) 2007-03-22 2008-09-25 Keck Graduate Institute Systems and devices for isothermal biochemical reactions and/or analysis
BRPI0812913B8 (pt) 2007-06-18 2021-05-25 Merck Sharp & Dohme anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
KR102197527B1 (ko) 2008-09-26 2020-12-31 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
KR20190069615A (ko) 2008-12-09 2019-06-19 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
JP6138813B2 (ja) 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体及びその使用
CA2910278C (en) 2013-05-02 2021-09-28 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
CN105683217B (zh) 2013-05-31 2019-12-10 索伦托治疗有限公司 与pd-1结合的抗原结合蛋白
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
CA3080200A1 (en) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
US10344090B2 (en) 2013-12-12 2019-07-09 Shanghai Hangrui Pharmaceutical Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
AU2016306090B2 (en) * 2015-08-11 2019-05-02 Novartis Ag 5-bromo-2,6-di-(1H-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
KR20190115053A (ko) * 2017-02-10 2019-10-10 노파르티스 아게 1-(4-아미노-5-브로모-6-(1h-피라졸-1-일)피리미딘-2-일)-1h-피라졸-4-올 및 암 치료에 있어서의 이의 용도
JOP20190279A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة

Also Published As

Publication number Publication date
CN110944995A (zh) 2020-03-31
AR111906A1 (es) 2019-08-28
EP3630751B1 (en) 2024-03-27
IL291721B2 (en) 2024-07-01
TWI814725B (zh) 2023-09-11
JP7273732B2 (ja) 2023-05-15
IL270795B1 (en) 2023-08-01
TW201920152A (zh) 2019-06-01
WO2018220546A1 (en) 2018-12-06
RU2019138329A (ru) 2021-07-01
US20210145831A1 (en) 2021-05-20
IL270795A (en) 2020-01-30
JOP20190279A1 (ar) 2019-11-28
CA3065475A1 (en) 2018-12-06
CL2019003468A1 (es) 2020-08-14
EP3630751A1 (en) 2020-04-08
IL291721B1 (en) 2024-03-01
US11654144B2 (en) 2023-05-23
BR112019025149A2 (pt) 2020-06-23
AU2018277241A1 (en) 2019-12-12
RU2019138329A3 (es) 2022-02-17
US10933064B2 (en) 2021-03-02
JP2020521774A (ja) 2020-07-27
KR20200018503A (ko) 2020-02-19
US20200163963A1 (en) 2020-05-28
CN110944995B (zh) 2024-03-12
RU2022102355A (ru) 2022-03-30
AU2018277241B2 (en) 2021-03-04
IL291721A (en) 2022-05-01
MX2021014104A (es) 2021-12-10
IL270795B2 (en) 2023-12-01
ZA201907610B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
AR124607A2 (es) Arilquinazolinas
CL2021002667A1 (es) Formas cristalinas de 5-bromo-2,6-di(1h -pirazol-1-il)pirimidin-4amina y nuevas sales (divisional solicitud n° 201903468).
SV2016005312A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer
AR111813A2 (es) Compuestos y composiciones para el control de nematodos
BR112018073199A2 (pt) corantes diméricos ou poliméricos ultrabrilhantes
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
AR101820A1 (es) Difluorometil-indanil-carboxamidas nicotínicas
ECSP10010366A (es) Derivados de pirimidina 5-fluoro como fungicidas
CR10874A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3 metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro benzonitrilo y metodos para el uso de los mismos
UY36966A (es) Derivados de heterociclos bicíclicos fusionados como plaguicidas
CR20180307A (es) Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
BR112013007123A2 (pt) processo de fabricação para derivados depirimidina
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
AR048938A1 (es) Cepas de levadura que producen colesterol y sus aplicaciones
DOP2017000188A (es) Compuestos de benzoxaborol 4-sustituidos y uso de los mismos
PA8658001A1 (es) Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos
CO2017001523A2 (es) Novedosas pirimidinas 2,5-sustituidas
CL2004000979A1 (es) Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida.